DRREDDY:NSE-Dr. Reddy's Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 4,297.80

Change

+37.00 (+0.87)%

Market Cap

INR 714.00B

Volume

0.26M

Avg Analyst Target

INR 4,862.31 (+13.13%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


DRREDDY Stock Forecast & Price:
Based on the Dr. Reddy's Laboratories Limited stock forecasts from 10 analysts, the average analyst target price for Dr. Reddy's Laboratories Limited is INR 4,862.31 over the next 12 months. Dr. Reddy's Laboratories Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Dr. Reddy's Laboratories Limited is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, Dr. Reddy's Laboratories Limited’s stock price was INR 4,297.80. Dr. Reddy's Laboratories Limited’s stock price has changed by +1.76% over the past week, -5.46% over the past month and -7.80% over the last year.

About Dr. Reddy's Laboratories Limited (DRREDDY:NSE)

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Globa ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+1.15 (+0.13%)

INR2,191.67B 56.39 28.48
DIVISLAB:NSE Divi's Laboratories Limited

+5.80 (+0.16%)

INR992.46B 33.52 25.55
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+33.75 (+2.19%)

INR529.33B 66.13 25.67
PEL:NSE Piramal Enterprises Limited

+5.35 (+0.28%)

INR455.79B 24.34 12.25
ALKEM:NSE Alkem Laboratories Limited

-9.60 (-0.32%)

INR353.08B 27.05 20.35
AUROPHARMA:NSE Aurobindo Pharma Limited

-9.45 (-1.59%)

INR343.04B 12.96 7.98
LUPIN:NSE Lupin Limited

+0.70 (+0.10%)

INR309.20B 25.10 -92.56
LAURUSLABS:NSE Laurus Labs Limited

+11.15 (+1.97%)

INR308.82B 37.01 21.64
IPCALAB:NSE IPCA Laboratories Limited

-2.10 (-0.23%)

INR235.87B 32.74 20.48
AJANTPHARM:NSE Ajanta Pharma Limited

-1.85 (-0.14%)

INR162.81B 22.86 15.33

ETFs Containing DRREDDY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.41% 70% C- 40% F
Dividend Return 0.61% 48% F 37% F
Total Return -11.80% 70% C- 40% F
Trailing 12 Months  
Capital Gain -8.39% 75% C 34% F
Dividend Return 0.64% 59% F 36% F
Total Return -7.75% 77% C+ 34% F
Trailing 5 Years  
Capital Gain 113.69% 70% C- 77% C+
Dividend Return 4.97% 80% B- 62% D-
Total Return 118.66% 72% C- 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 22.18% 54% F 59% F
Dividend Return 0.58% 58% F 45% F
Total Return 22.76% 55% F 59% F
Risk Return Profile  
Volatility (Standard Deviation) 28.37% 89% B+ 86% B
Risk Adjusted Return 80.22% 92% A- 93% A
Market Capitalization 714.00B 97% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.06 46% F 44% F
Price/Book Ratio 3.53 39% F 32% F
Price / Cash Flow Ratio 25.40 38% F 26% F
EV/EBITDA 13.26 51% F 38% F
Management Effectiveness  
Return on Equity 15.71% 65% D 65% D
Return on Invested Capital 13.24% 65% D 72% C-
Return on Assets 7.81% 67% D+ 73% C
Debt to Equity Ratio 3.02% 65% D 71% C-
Technical Ratios  
Dividend Yield 0.70% 46% F 40% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.23 93% A 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.